2023-2028 Europe Automated Microbiology Market in 38 Countries--Growth Opportunities, 2023 Supplier Shares by Assay, Volume and Sales Five-Year Segmentation Forecasts for over 100 Molecular, Identification, Susceptibility, Culture, Urine Screening and Immunodiagnostic Tests--Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks
This new 38-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.
The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the automated microbiology market during the next five years.The report is available by section, and can be customized to specific information needs and budget. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratories still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive 38-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Country Analyses
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Specimen Types
-Microbial Identification
-Antibiotic Susceptibility
-Urine Screening
-Blood Cultures
Review of Major Automated Systems
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Technology Review
The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the automated microbiology market during the next five years.The report is available by section, and can be customized to specific information needs and budget. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratories still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive 38-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Country Analyses
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Specimen Types
- Urine
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Stool
- Abscess/Wound
- Sputum
- Saliva
-Microbial Identification
-Antibiotic Susceptibility
-Urine Screening
-Blood Cultures
Review of Major Automated Systems
- Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Halifax, BD, Beckman Coulter/Danaher, Biolog, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Hologic, HTG, Labsystems, Qiagen, Roche, Siemens Healthineers, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers.
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Technology Review
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market.
- Companies developing or marketing microbiology products, by individual test.
- Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
- Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
I. Introduction
II. Automated Microbiology Market Business Environment
III. New Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Market and Technology Overview
A. Introduction
1. MAJOR FACTORS AFFECTING MARKET PENETRATION FOR MICROBIOLOGY INSTRUMENTATION
2. TRADITIONAL PRACTICES
3. TECHNOLOGICAL CHALLENGES
4. AUTOMATION: IMPACT ON THE MICROBIOLOGY LABORATORY AND THE PATIENT
B. Major Specimen Types
1. URINE
2. STERILE FLUIDS: BLOOD, SERUM, AND CSF
3. THROAT SWABS AND RESPIRATORY SECRETIONS
4. GENITAL SECRETIONS
5. STOOL
6. ABSCESS/WOUND
7. SPUTUM
8. SALIVA
C. Test Applications
1. MICROBIAL IDENTIFICATION
2. ANTIBIOTIC SUSCEPTIBILITY
3. URINE SCREENING
a. Photometry
b. Bioluminescence
c. Colorimetric Filtration
d. Enzymatic Detection
e. Optical Detection
4. BLOOD CULTURES
D. Major Automated and Semi-automated Microbiology Systems
1. MULTIPLE PURPOSE MICROBIOLOGY SYSTEMS
2. SPECIALIZED MICROBIOLOGY SYSTEMS
3. MOLECULAR DIAGNOSTIC SYSTEMS
4. IMMUNODIAGNOSTIC SYSTEMS
E. Emerging Diagnostic Technologies
1. MOLECULAR DIAGNOSTICS (AMPLIFICATION METHODS, SEQUENCING, MICROARRAYS/BIOCHIPS)
a. DNA Sequencing
b. DNA and RNA Probe Technologies
c. Detection Technologies
d. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
2. MONOCLONAL ANTIBODIES
3. IMMUNOASSAYS
4. DIFFERENTIAL LIGHT SCATTERING
5. INFORMATION TECHNOLOGY
6. ARTIFICIAL INTELLIGENCE
7. LIPOSOMES
8. FLOW CYTOMETRY
9. CHROMATOGRAPHY
10. DIAGNOSTIC IMAGING
11. GEL MICRODROPLETS
12. OTHER
VIII. 38-Country Analyses: Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial
Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic
Tests, Supplier Shares
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia,
Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia,
Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
IX. Competitive
Assessments
- Abbott Laboratories
- Agilent Technologies
- Beckman Coulter/Danaher
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Fujifilm Wako
- Fujirebio
- Grifols
- Instrumentation Laboratory/Werfen
- Kyowa Medex
- OrthoQuidel
- PerkinElmer
- Quest Diagnostics
- Roche
- Siemens Healthineers
- Sysmex
- Thermo Fisher
- Tosoh
II. Automated Microbiology Market Business Environment
III. New Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Market and Technology Overview
A. Introduction
1. MAJOR FACTORS AFFECTING MARKET PENETRATION FOR MICROBIOLOGY INSTRUMENTATION
2. TRADITIONAL PRACTICES
3. TECHNOLOGICAL CHALLENGES
4. AUTOMATION: IMPACT ON THE MICROBIOLOGY LABORATORY AND THE PATIENT
B. Major Specimen Types
1. URINE
2. STERILE FLUIDS: BLOOD, SERUM, AND CSF
3. THROAT SWABS AND RESPIRATORY SECRETIONS
4. GENITAL SECRETIONS
5. STOOL
6. ABSCESS/WOUND
7. SPUTUM
8. SALIVA
C. Test Applications
1. MICROBIAL IDENTIFICATION
2. ANTIBIOTIC SUSCEPTIBILITY
3. URINE SCREENING
a. Photometry
b. Bioluminescence
c. Colorimetric Filtration
d. Enzymatic Detection
e. Optical Detection
4. BLOOD CULTURES
D. Major Automated and Semi-automated Microbiology Systems
1. MULTIPLE PURPOSE MICROBIOLOGY SYSTEMS
2. SPECIALIZED MICROBIOLOGY SYSTEMS
3. MOLECULAR DIAGNOSTIC SYSTEMS
4. IMMUNODIAGNOSTIC SYSTEMS
E. Emerging Diagnostic Technologies
1. MOLECULAR DIAGNOSTICS (AMPLIFICATION METHODS, SEQUENCING, MICROARRAYS/BIOCHIPS)
a. DNA Sequencing
b. DNA and RNA Probe Technologies
c. Detection Technologies
d. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
2. MONOCLONAL ANTIBODIES
3. IMMUNOASSAYS
4. DIFFERENTIAL LIGHT SCATTERING
5. INFORMATION TECHNOLOGY
6. ARTIFICIAL INTELLIGENCE
7. LIPOSOMES
8. FLOW CYTOMETRY
9. CHROMATOGRAPHY
10. DIAGNOSTIC IMAGING
11. GEL MICRODROPLETS
12. OTHER
VIII. 38-Country Analyses: Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial
Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic
Tests, Supplier Shares
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia,
Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia,
Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
IX. Competitive
Assessments
- Abbott Laboratories
- Agilent Technologies
- Beckman Coulter/Danaher
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Fujifilm Wako
- Fujirebio
- Grifols
- Instrumentation Laboratory/Werfen
- Kyowa Medex
- OrthoQuidel
- PerkinElmer
- Quest Diagnostics
- Roche
- Siemens Healthineers
- Sysmex
- Thermo Fisher
- Tosoh
